Semaglutide statistics 2026: Ozempic and Wegovy prescriptions, sales, trial results and compounding

Medicare Part D enrollees took Ozempic in 2024, up from fewer than 150,000 in 2019¹

Ozempic claims were filled in Medicare Part D in 2024, up from 524,000 in 2019¹

of the 88.2 million Ozempic, Mounjaro, Wegovy and Zepbound prescriptions dispensed from January 2023 to September 2024 were for Ozempic²

Wegovy accounted for 14%. IQVIA National Prescription Audit data.

of Wegovy prescriptions were written for female patients, compared with 59% of Ozempic prescriptions²

January 2023 to September 2024.

weekly US Wegovy prescriptions, around mid-2025³

Novo Nordisk first-half 2025 report.

weekly self-pay prescriptions for injectable Wegovy through NovoCare Pharmacy as of January 23, 2026⁴

prescriptions for the Wegovy pill (oral semaglutide) were filled in the second quarter of 2026⁵

More than 5 million since launch; weekly prescriptions exceeded 265,000 in the week ending July 17, 2026.

of young adults ages 18 to 25 dispensed a GLP-1 in 2023 had Ozempic as their most recent GLP-1, more than any other drug⁶

Wegovy accounted for 21.7% (IQVIA prescription data).

Ozempic worldwide sales in 2025, up 6% in Danish kroner and 10% at constant exchange rates⁴

Wegovy worldwide sales in 2025, up 36% in Danish kroner and 41% at constant exchange rates⁴

Wegovy sales in the US in 2025, up 16% at constant exchange rates⁴

International Wegovy sales were DKK 28,091 million, up 134% at constant exchange rates.

Ozempic worldwide sales in the first half of 2026, down 2% at constant exchange rates⁵

decline in US sales of injectable Wegovy in the first half of 2026 at constant exchange rates⁵

International sales of injectable Wegovy rose 53% over the same period.

Wegovy pill sales in the first half of 2026, of which DKK 5,397 million were in the US⁵

patients were using Novo Nordisk obesity care products in the first half of 2026⁵

Moving annual total for Novo Nordisk's obesity care portfolio.

average body weight loss over 68 weeks with semaglutide 2.4 mg in STEP 1, vs 2.4% with placebo⁷

1,961 adults with overweight or obesity who did not have diabetes; average loss was 15.3 kg vs 2.6 kg.

of STEP 1 participants on semaglutide lost 15% or more of body weight, vs 4.9% on placebo⁷

86.4% lost at least 5% and 69.1% at least 10%.

average weight loss over 72 weeks with Wegovy HD 7.2 mg in the STEP UP trial, vs 17.5% with Wegovy 2.4 mg⁸

Efficacy estimand (assumes participants stayed on treatment). Regardless of adherence, the figures were 18.8% and 15.5%. Reported by Novo Nordisk.

average weight loss over 64 weeks with oral semaglutide 25 mg, vs 2.2% with placebo⁹

body weight change from week 20 to week 68 for people who continued semaglutide vs those switched to placebo in STEP 4¹⁰

Participants had lost an average of 10.6% during the 20-week run-in.

of STEP 1 participants on semaglutide stopped treatment because of gastrointestinal side effects, vs 0.8% on placebo⁷

of SELECT participants had a major cardiovascular event (cardiovascular death, heart attack or stroke) on semaglutide vs placebo¹¹

17,604 adults with established cardiovascular disease and overweight or obesity but no diabetes; hazard ratio 0.80; mean follow-up 39.8 months.

of SELECT participants on semaglutide permanently stopped the drug because of adverse events, vs 8.2% on placebo¹¹

date the FDA approved Wegovy to reduce the risk of serious heart problems in adults with obesity or overweight and cardiovascular disease¹²

lower risk of the primary kidney outcome with semaglutide vs placebo in the FLOW trial in people with type 2 diabetes and chronic kidney disease¹³

Hazard ratio 0.76; 3,533 participants; median follow-up 3.4 years. Death from any cause was 20% lower.

year semaglutide injection products went into shortage due to increased demand¹⁴

date the FDA determined the semaglutide injection shortage was resolved¹⁴

original end of FDA enforcement discretion for state-licensed pharmacies (503A) compounding semaglutide¹⁴

FDA confirmed the period had ended after an April 24, 2025 court ruling. The period for outsourcing facilities (503B) ran until May 22, 2025.

adverse event reports linked to compounded semaglutide had been received by the FDA as of May 31, 2026¹⁵

Some reports involved dosing errors that required hospitalization.

date the FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list used by outsourcing facilities¹⁶

Comments were due June 29, 2026.

list price (WAC) of a four-pen package of injectable Wegovy, the same for every dose¹⁷

Novo Nordisk pricing page dated March 2026.

monthly self-pay price for Wegovy and most Ozempic doses since November 17, 2025, down from $499¹⁸

Ozempic 2 mg remained $499 per month.

new list price for Wegovy and certain Ozempic doses from January 1, 2027, about 50% lower for Wegovy and 35% lower for Ozempic⁵